BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38187140)

  • 1. Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response.
    Alors-Pérez E; Pedraza-Arevalo S; Blázquez-Encinas R; García-Vioque V; Agraz-Doblas A; Yubero-Serrano EM; Sánchez-Frías ME; Serrano-Blanch R; Gálvez-Moreno MÁ; Gracia-Navarro F; Gahete MD; Arjona-Sánchez Á; Luque RM; Ibáñez-Costa A; Castaño JP
    Mol Ther Nucleic Acids; 2024 Mar; 35(1):102090. PubMed ID: 38187140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spliceosomic dysregulation unveils NOVA1 as a candidate actionable therapeutic target in pancreatic neuroendocrine tumors.
    Pedraza-Arevalo S; Alors-Pérez E; Blázquez-Encinas R; Herrera-Martínez AD; Jiménez-Vacas JM; Fuentes-Fayos AC; Reyes Ó; Ventura S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Gálvez-Moreno MA; Gahete MD; Ibáñez-Costa A; Luque RM; Castaño JP
    Transl Res; 2023 Jan; 251():63-73. PubMed ID: 35882361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression analysis of Sfrs10 and Celf4 during mouse retinal development.
    Karunakaran DK; Congdon S; Guerrette T; Banday AR; Lemoine C; Chhaya N; Kanadia R
    Gene Expr Patterns; 2013 Dec; 13(8):425-36. PubMed ID: 23932931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus.
    Cen P; Amato RJ
    Onco Targets Ther; 2012; 5():217-24. PubMed ID: 22870038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.
    Soler A; Figueiredo AM; Castel P; Martin L; Monelli E; Angulo-Urarte A; Milà-Guasch M; Viñals F; Baselga J; Casanovas O; Graupera M
    Clin Cancer Res; 2016 Dec; 22(23):5805-5817. PubMed ID: 27225693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEN1 Degradation Induced by Neddylation and the CUL4B-DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression.
    Xu J; Ye Z; Zhuo Q; Gao H; Qin Y; Lou X; Zhang W; Wang F; Wang Y; Jing D; Fan G; Zhang Y; Chen X; Chen J; Xu X; Yu X; Ji S
    Cancer Res; 2023 Jul; 83(13):2226-2247. PubMed ID: 36939378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives.
    Marini F; Giusti F; Brandi ML
    Expert Rev Endocrinol Metab; 2021 Nov; 16(6):295-307. PubMed ID: 34554891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FAM83A promotes the progression and metastasis of human pancreatic neuroendocrine tumors by inducing the epithelial-mesenchymal transition via the PI3K/AKT and ERK pathways.
    Zhou B; Zhou X; Zhan C; Jin M; Yan S
    J Endocrinol Invest; 2023 Jun; 46(6):1115-1130. PubMed ID: 36344884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
    Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
    Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST
    Pedraza-Arevalo S; Ibáñez-Costa A; Blázquez-Encinas R; Branco MR; Vázquez-Borrego MC; Herrera-Martínez AD; Venegas-Moreno E; Serrano-Blanch R; Arjona-Sánchez Á; Gálvez-Moreno MA; Korbonits M; Soto-Moreno A; Gahete MD; Charalambous M; Luque RM; Castaño JP
    Mol Oncol; 2022 Feb; 16(3):764-779. PubMed ID: 34601790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features.
    Vázquez-Borrego MC; Fuentes-Fayos AC; Venegas-Moreno E; Rivero-Cortés E; Dios E; Moreno-Moreno P; Madrazo-Atutxa A; Remón P; Solivera J; Wildemberg LE; Kasuki L; López-Fernández JM; Gadelha MR; Gálvez-Moreno MA; Soto-Moreno A; Gahete MD; Castaño JP; Luque RM
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31561558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
    Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
    Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine pancreatic tumors: guidelines for management and update.
    Burns WR; Edil BH
    Curr Treat Options Oncol; 2012 Mar; 13(1):24-34. PubMed ID: 22198808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
    Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
    J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
    Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
    J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etiology of a genetically complex seizure disorder in Celf4 mutant mice.
    Wagnon JL; Mahaffey CL; Sun W; Yang Y; Chao HT; Frankel WN
    Genes Brain Behav; 2011 Oct; 10(7):765-77. PubMed ID: 21745337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs.
    Ueda H; Akiyama Y; Shimada S; Mogushi K; Serizawa M; Matsumura S; Mitsunori Y; Aihara A; Ban D; Ochiai T; Kudo A; Tanabe M; Tanaka S
    Endocr Relat Cancer; 2018 Jun; 25(6):619-631. PubMed ID: 29599123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convergence between germline and somatic mutations in pancreatic neuroendocrine tumors.
    Ling C; Hong X; Xu M; Wang Y; Ma X; Cui Y; Jiang R; Cao D; Wu H; Tong A; Zhao Y; Wu W
    Eur J Endocrinol; 2022 May; 187(1):85-90. PubMed ID: 35521758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.